SecBot SecBot
8-K ·Filed May 22, 2026

ONCY

ONCOLYTICS BIOTECH INC
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001129928-26-000035
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor ASCO presentation on May 30 for any additional data or commentary that could move the stock. Without new efficacy or safety endpoints, this filing is unlikely to be a near-term catalyst.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.8100
T+0 close · May 22, 2026 · via day close
Latest settled
+4.30%
T+60 · $0.8448
Vs SPY
+1.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $0.8100entry
  2. T+1 · 6mo ago 0.00%α −0.59% · $0.8100
  3. T+5 · 6mo ago +30.86%α +29.19% · $1.06
  4. T+20 · 5mo ago +14.81%α +16.23% · $0.9300
  5. T+60 · 3mo ago +4.30%α +1.11% · $0.8448
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2026, showing pelareorep activates innate and adaptive immune responses and expands mutant KRAS-specific T cells. The press release contains no new financial information or definitive clinical outcomes, making this a routine scientific update.

Key Facts

  • Data will be presented at ASCO 2026 (May 29-June 2) on pelareorep's mechanism of action.
  • Translational analyses show pelareorep induces antiviral and anti-tumor immune responses.
  • Expansion of mutant KRAS-specific T cell clones correlated with tumor volume reduction in pancreatic cancer.
  • AWARE-1 breast cancer biopsies showed increased CXCL13 and tertiary lymphoid structure formation.
  • No financial figures, guidance, or clinical endpoints were disclosed.

Financial Impact

No financial impact reported.

Risk Factors

  • Translational data may not translate into clinical efficacy in ongoing trials.
  • No update on cash runway or regulatory milestones.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001129928-26-000035
Document: asco2026pressrelease.htm0001129928-26-000035
Document: 0001129928-26-000035-index-headers.html0001129928-26-000035
Document: 0001129928-26-000035-index.html0001129928-26-000035
Document: 0001129928-26-000035.txt0001129928-26-000035

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026